Literature & Validation

This experimental study investigates fouling mitigation strategies for plasmid DNA ultrafiltration — a biofluids class directly analogous to the viral vectors and extracellular vesicles that constitute the primary target applications of AFRM®. Plasmid DNA is among the most mechanically labile biomolecules processed through TFF: it is highly shear-sensitive, prone to pore entrapment, and structurally damaged by aggressive backwash events.

The finding is mechanistically decisive: pore clearing in shear-sensitive biologics depends on tangential drag forces, not on pressure reversal through the membrane. A momentary interruption of permeate flow — without any back-pressure — is sufficient to restore flux, provided crossflow velocity is adequate. This is the precise operating mode of AFRM® hydrodynamic transients: brief, controlled, non-invasive, and structurally conservative.

Cirillo et al. provide a systematic review of the mathematical models governing membrane fouling — specifically the Hermia blocking laws framework — and their applicability across filtration scales from microfluidic to industrial. The review directly addresses the discrete, physically classifiable nature of fouling progression.

The formalism validated here — complete blocking (n = 2), intermediate blocking (n = 1.5), standard blocking (n = 1), and cake filtration (n = 0) — is the same classification structure that underlies the AFRM® control architecture. The fact that each fouling regime maps to a discrete exponent with a distinct physical interpretation is what enables deterministic pre-computation of intervention timing: the system does not require empirical detection of a state it has already been designed to prevent.

The process intensification dimension is equally relevant: Cirillo frames reduced footprint and energy demand as intrinsic to membrane technology when fouling is properly managed — a framing consistent with the operational efficiency claims of AFRM®.

This pharmaceutical industry review from Eli Lilly synthesises TFF process development practice across the full spectrum from laboratory development to commercial-scale continuous bioprocessing. It represents the state of the art of TFF deployment in regulated GMP environments — precisely the operational context for which AFRM® is designed.

Agrawal confirms the central engineering constraint: TFF scaling is governed by membrane surface area, and the parameters established at laboratory scale must transfer without retuning. This is precisely the condition that AFRM® addresses — the deterministic, scale-invariant kinetic model eliminates the empirical retuning step that represents the primary source of scale-up failure in viscous or high-concentration pharmaceutical matrices.

The review also acknowledges the practical difficulty of maintaining the crossflow-gel-layer equilibrium in complex biological feeds — the same instability that AFRM® targets with controlled hydrodynamic transients calibrated to the fastest-consolidating component.

Note on scope: this study operates in a different application domain (microalgae harvesting for biofuel) rather than pharmaceutical bioprocessing. Its inclusion here is justified by the universality of its economic conclusion, which applies to any pressure-driven membrane filtration process where antifouling strategies improve permeability.

Ríos et al. quantify what the fouling mitigation literature often leaves implicit: the primary economic driver in membrane filtration is not energy cost but capital expenditure on membrane modules. Strategies that increase sustained permeability reduce the required membrane area, and because module count is among the most cost-sensitive variables in the entire system, even moderate permeability improvements produce disproportionate CAPEX reductions.

This finding provides the economic rationale that completes the AFRM® value proposition: stabilising flux through deterministic fouling prevention does not merely reduce cleaning agent consumption and membrane replacement frequency — it directly reduces the membrane area that must be installed and maintained, which is the dominant cost lever in scaled continuous bioprocessing.

This study by Purdue University in collaboration with Eli Lilly combines two first-of-a-kind measurement approaches: intramodule pressure sensors distributed along the length of an operational TFF cassette, and confocal laser scanning microscopy (CLSM) of the membrane surface under process conditions. The substrate is bovine IgG (150 kDa), directly analogous to the mAb and high-molecular-weight biologics that constitute AFRM®'s primary target applications.

The 50 μm gel layer thickness documented here is not a modelling artefact — it is a direct physical measurement from 3D confocal imaging under operational process conditions. The study also confirms that axial pressure drops within the module are substantial and spatially non-uniform, undermining the validity of single TMP values as process descriptors. Both findings directly support the AFRM® premise: the fouling layer is a quantifiable, physically real structure that develops predictably, and any effective intervention must be timed to act before this structure consolidates.

Published by the Braatz group at MIT — one of the leading academic groups in continuous pharmaceutical manufacturing — this paper presents a full digital twin platform for end-to-end continuous mRNA production (IVT → TFF → chromatography → LNP formulation → lyophilization). The TFF module is modelled mechanistically using critical flux, stagnant film, and conversion models, and a Morris global sensitivity analysis identifies which parameters most influence mRNA yield and processing time.

The sensitivity analysis in the paper further confirms that inlet mRNA concentration and crossflow rate are the dominant determinants of TFF outcome — not pump settings or buffer composition. This is precisely the operating space in which AFRM® intervenes: by maintaining stable flux through controlled hydrodynamic transients, the module keeps the process within the critical flux envelope throughout the batch, preventing the transitions that would otherwise degrade yield and require intervention.

The mRNA context is directly relevant: mRNA molecules are among the most shear-sensitive and fouling-prone substrates in bioprocessing, and a failed TFF step has downstream consequences that propagate through LNP formulation and final product quality.

Krippl et al. develop and validate a hybrid model (physics-based white box + neural network black box) for single-pass TFF across serial and parallel configurations. The model is trained on a single batch-mode experiment and then used to predict performance across pressure, flow rate, and concentration space. In characterising the operating regimes of SPTFF, the paper identifies and quantifies the pressure-dependent behaviour of the concentration polarization layer at the membrane surface.

This is the mechanistic description of the compaction event that AFRM® is designed to prevent. In the pressure-dependent regime, each increment of transmembrane pressure physically compresses the polarization layer, reducing its porosity and increasing its hydraulic resistance. Once the process transitions to the pressure-independent regime, the layer has consolidated into a cake whose removal requires structural disruption — exactly the class of intervention that stresses shear-sensitive molecules and interrupts process flow.

The deterministic character of this transition — governed by physical constants, membrane geometry, and feed composition rather than by stochastic events — is what makes pre-computational intervention timing possible. AFRM® exploits this determinism: by acting before the pressure-dependent-to-independent transition, the module prevents compaction rather than correcting it.

Published by the same Purdue / Eli Lilly group responsible for Cunha et al. (2023), this paper proposes a complete framework for deterministic modelling, sensitivity analysis, and dynamic optimization of TFF systems — using bovine IgG as a mAb analog. Its principal contribution relevant to AFRM® is the formal introduction of the Gel number (Ge), a new dimensionless parameter that completes the kinetic description of the membrane surface alongside the already-established Péclet number (Pe).

The Gel number formalises what AFRM® addresses operationally: the balance between the rate at which protein deposits onto the membrane surface and the rate at which convective transport removes it. When Ge exceeds a critical threshold, the gel layer transitions from reversible to compacted — the exact transition that AFRM® hydrodynamic transients are pre-computed to prevent. The paper also demonstrates that the deterministic framework predicts TFF performance across scales from a single training dataset, with the sensitivity analysis confirming that gel layer void fraction and mixing conditions dominate process outcomes — findings fully consistent with the AFRM® control rationale.

Importantly, the paper explicitly classifies fully data-driven models (including AI/neural network approaches) as offering "limited predictive power and minimal process phenomenological understanding" — unsuitable for comprehensive sensitivity analysis or optimization. This is the same conclusion that motivates AFRM®'s architectural choice to operate on physical constants rather than trained models.

This review examines the state of quantitative PAT tools and real-time release testing (RTRT) in continuous downstream processing of mAbs — exactly the operational context in which AFRM® is deployed. Its relevance to the AFRM® architecture is not in what it recommends, but in what it documents as an unresolved industrial constraint.

This is a documented regulatory reality, not a theoretical limitation. Regulatory authorities (FDA, EMA) have not yet established consolidated approval pathways for AI-based control architectures in GMP bioprocessing. A control system that relies on a trained model — rather than on validated physical constants — cannot be submitted through the standard IQ/OQ/PQ pathway, and its GMP compliance cannot be demonstrated by the structural arguments available to deterministic systems.

AFRM® was designed to be exempt from this constraint by construction. The control signal is derived from blocking law classification and dimensionless kinetic parameters — quantities that are pre-validated from physical first principles, independent of any training dataset, and structurally invariant across scale. This is not a preference for simplicity over capability; it is the only architecture that currently offers a clear GMP compliance pathway in the absence of regulatory guidance for AI-based process control.